Con prednisolone standard-release (non MR/Lodotra) alle 23:30, il picco

The pharmacokinetic profile of standard-release oral prednisolone demonstrates rapid and almost complete absorption, reaching peak plasma concentrations typically within 1 to 3 hours after administration, with a biological half-life of approximately 3 hours in adults. When administered at 23:30, the peak plasma prednisolone levels occurring between 01:00 and 02:00 correspond well with this known absorption profile of immediate-release formulations SmPC Prednisolone,SmPC Prednisolone,SmPC Prednisolone,SmPC Prednisolone.

In contrast, modified-release formulations of corticosteroids, such as modified-release hydrocortisone, are designed to mimic circadian rhythms and provide delayed or sustained drug release to optimise physiological glucocorticoid replacement or anti-inflammatory effects, potentially altering timing of peak plasma levels and thereby cytokine suppression profiles, including interleukin-6 (IL-6) coverage NICE NG243.

Preclinical studies evaluating solid lipid nanoparticle (SLN) formulations of prednisolone and related corticosteroids have demonstrated that these modified-release systems can prolong circulation time, enhance joint or tissue-specific accumulation, and provide a sustained release profile, resulting in superior suppression of inflammatory mediators such as IL-6 compared with standard formulations. Hyaluronic acid-coated prednisolone SLNs accumulate preferentially in inflamed synovial tissue, achieving higher local drug concentrations and more effective IL-6 coverage over extended periods Ramesh et al. 2026.

This targeted and sustained release profile of modified-release or nanoparticle-based prednisolone formulations differs significantly from the pharmacokinetics of standard immediate-release prednisolone tablets, which show more rapid absorption and clearance, resulting in a sharper and earlier plasma concentration peak. Consequently, the immunomodulatory effects, including peak IL-6 suppression, may not coincide temporally with the inflammatory cytokine peaks observed in various disease states.

Therefore, while standard-release prednisolone taken at 23:30 achieves plasma peak levels around 1.5 to 2.5 hours later, modified-release formulations exert pharmacokinetic modulation through sustained drug release and preferential tissue targeting, which can extend and perhaps shift the timing of peak anti-inflammatory activity including IL-6 inhibition. This difference in release profiles can translate into improved therapeutic coverage of cytokine-driven inflammation Ramesh et al. 2026 SmPC Prednisolone,SmPC Prednisolone,SmPC Prednisolone,SmPC Prednisolone,NICE NG243.

Given these distinctions, standard-release prednisolone tablets are not pharmacokinetically equivalent to modified-release formulations regarding timing and duration of peak plasma levels and consequent cytokine suppression. This can have clinical implications depending on the inflammatory disease context where precise timing of peak IL-6 coverage may influence therapeutic efficacy.